Challenges with Rx and managing it effectively
Rx costs continue to rise
With the approvals of innovative Cell and Gene therapies, pharmacy trends are not expected to slow down in 2024. The inflationary impact of pharmaceutical pricing is expected to be in the high single or double digits from 2023-24.
Managing drug costs feels complicated and overwhelming
The U.S. healthcare system is complex enough let alone trying to figure out how to navigate, manage, and contain Rx costs. There are a ton of players and solution providers out there that makes it more confusing.
PBMs often have misaligned interests
The PBM industry has not been seen in the best light by often times generating revenue that isn't fully aligned to healthier member outcomes or bottom line savings for their clients.
How RedSpruce can help
SIMPLIFY
We recognize that managing drug costs can be confusing. Our goal is to simplify the process and make it easier for everyone involved.
ALIGN
Our desired outcome is to build a long term partnership with our clients that is fully aligned to delivering savings year over year while providing outstanding member service.
ADJUST
The healthcare system never sits still and nor do we. We have to continually stay ahead of new trends, legislation, and potential new partnerships to ensure we consistently deliver.
Here’s how we deliver results
Foundation
By leveraging one of the most robust PBM backbones in the industry, our platform delivers exceptional member service and bottom line results
Analyze
Pinpointing cost drivers within both the pharmacy & medical benefits is crucial for planning and optimizing the setup for each group
Optimize
Based upon the group's makeup, our team will offer a range of setup options to ensure low member disruption while maximizing savings opportunities
Measure
Once implemented, we'll continually measure our results and identify any new high cost drug claims to proactively manage & mitigate costs
Here's what we need to deliver an initial analysis
Our Analysis
- Repriced claim report
- Initial set of recommendations
- Deeper discovery call to determine fit